[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Cell Therapy Market & Clinical Pipeline Outlook 2022

November 2016 | 850 pages | ID: G19EEDFFE8EEN
Kuick Research

US$ 2,400.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Cell Therapy Market & Clinical Pipeline Outlook 2022” report published by Kuick Research gives comprehensive insight on the ongoing clinical and nonclinical trends in the global cell therapy market. Report analyzes the need and the application of cell therapy in multiple therapeutic areas along with the mechanism and delivery methods for cell therapy based treatment. The parameters impacting the growth of the market and the corresponding challenges limiting the commercialization of cell therapies are explained in the report.

The idea of cell therapy was in pharmaceutical industry for several decades but significant development was not made due to technological challenges. In recent years, cell therapy has gained widespread acceptance among physicians and patients due to its ability to treat various diseases. Several decades of research and development has allowed the investigators to come forth with solutions which can’t be provided by conventional therapeutics. Theoretically, it could be used to cure plethora of diseases but underdeveloped technology has limited its usage to limited indications.

Several indications have been found to be curable with the help of cell therapies and indications are expected to be increased in near future. Cerebral disorders like Parkinson’s disease and Alzheimer’s disease are under investigation for treatment with the help of cell therapies. They are also being investigated for cardiovascular disease in which their aim is to restore normal heart functions. Investigators are also trying to find their safety and efficacy in treating various malignancies. On-going research is also aimed at curing metabolic disorder like diabetes mellitus type 1 in which patients tends to lack insulin production. Investigators are trying to restore the function of liver and kidney by supplementing them with modified cell of respective origins. Several clinical trials have been instigated across the globe in which their efficacy against different disease is being studies.

Cell therapy has potential in tissue development and regenerative medicine that could be used to make functional body parts. However, such researches are limited to laboratory levels and it will take very long time before successful instigation of clinical trials. Chances of their success are high as they have been able to develop the basic frame work in which conditions for growing different cells have been standardized. Now focus is on development of biocompatible matrix over which these cells could grow in predefined shape. Some materials have been found that are degraded from the system leaving behind the layer of cells in that shape. This shows that their approach is workable and someday they may be able to develop fully functional human organs.

Different individuals may respond to these therapies in different way and some of them develop hypertensive reaction during course of treatment. Some skeptics have raised concerns about safety of such treatment because more underlying principles have yet to be deciphered. For efficient treatment it is necessary to maintain their viability for elongated time and investigators are trying to figure out such methods. Cell therapy has significant commercialization potential but lots of work has yet to be done because its long-term effect on body is not known.

“Global Cell Therapy Market & Clinical Pipeline Outlook 2022” Highlights:
  • Introduction & Classification of Cell Therapies
  • Mechanism of Cell Therapy
  • Global Cell Therapy Market Analysis
  • Role of Stem Cells in Cell Therapy
  • Global Cell Therapy Clinical Pipeline by Country, Indication & Phase
  • Global Cell Therapy Clinical Pipeline: 476
  • Marketed Cell Therapies: 20
1. INTRODUCTION TO CELL THERAPY

2. NECESSITY FOR CELL THERAPY TREATMENT

2.1 Emergence of Stem Cell Research
2.2 Benefits of Using the Stem Cell for Research & Treatment

3. APPLICATION OF STEM CELLS IN CELL THERAPY

3.1 Stem Cells Ability to Differentiate
  3.1.1 Totipotent Stem Cells
  3.1.2 Pluripotent Stem Cells
  3.1.3 Multipotent Stem Cells
  3.1.4 Unipotent Stem Cells
3.2 Origin of Stem Cells
  3.2.1 Embryonic Stem Cells
  3.2.2 Adult Stem Cells
  3.2.3 Induced Pluripotent Stem Cells (iPSCs)

4. APPLICATIONS OF CELL THERAPY BY THERAPEUTIC AREA

4.1 Cell Therapy for Cardiovascular Diseases
4.2 Cell Therapy for Neurological Disorders
4.3 Cell Therapy for Inflammatory Diseases
4.4 Cell Therapy for Diabetes
4.5 Cell Therapy for Cancer
4.6 Cancer Stem Cells Therapy
  4.6.1 Therapies of Targeting the Cancer Stem Cells
    4.6.1.1 Targeting the Surface Markers
    4.6.1.2 Targeting the Signal Cascades
    4.6.1.3 Targeting the Microenvironment

5. MECHANISM OF CELL THERAPY

5.1 Two Major Mechanism Principles of Stem Cell Based Therapy
  5.1.1 Interaction of Modified Cells with Body
    5.1.1.1 Stem Cell Paracrine Actions in Heart Repair
  5.1.2 Mechanism of Regenerative Cell Therapy
    5.1.2.1 Regenerative Medicine Therapies for Diabetes
5.2 Mechanism of Action in Alzheimer’s Diseases

6. DELIVERY METHOD OF CELL BASED THERAPY

6.1 Outline to Delivery Methods
6.2 Direct Delivery Methods
  6.2.1 Intravascular Infusions
  6.2.2 Trans- Mucosal Delivery
6.3 Indirect Delivery of the Cells by Using the Carrier
  6.3.1 Natural Biomaterials
  6.3.2 Synthetic Biomaterials

7. MECHANISM OF CELL THERAPY TREATMENT

7.1 Allogeneic Stem Cell Therapy
7.2 Autologous Stem Cell Therapy

8. GLOBAL CELL THERAPY MARKET OVERVIEW

8.1 Current Market Scenario
8.2 Current Trends of Cell Therapy in Global Market
8.3 Global Cell Therapies Clinical Pipeline Overview

9. GLOBAL CELL THERAPY MARKET BY REGION

9.1 North America
9.2 Europe
9.3 Asia
9.4 Rest of the World

10. GLOBAL CELL THERAPY MARKET DYNAMICS

10.1 Favorable Market Parameters
10.2 Factors Limiting Market Growth

11. GLOBAL CELL THERAPY MARKET FUTURE PROSPECT

12. GLOBAL CELL THERAPIES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-0
12.6 Phase-I
12.7 Phase-I/II
12.8 Phase-II
12.9 Phase-II/III
12.10 Phase-III
12.11 Preregistration
12.12 Registered

13. MARKETED CELL THERAPIES CLINICAL INSIGHT BY COMPANY & INDICATION

13.1 T-Lymphocyte Cell Therapy (Immuncell-LC)
13.2 Muscle-Derived Autologous Stem Cell Therapy (MyoCell & MyoCell SDF-1)
13.3 Azficel-T (Laviv)
13.4 Sipuleucel-T (Provenge)
13.5 Placental Derived Mesenchymal Stem Cell Therapy - Osiris Therapeutics
13.6 Remestemcel-L (Prochymal & TEMCELL HS Inj.)
13.7 Autologous Mesenchymal Stem Cell Therapy – Pharmicell
13.8 Autologous Cultured Chondrocytes (MACI)
13.9 Mesenchymal Stem Cell Therapy for Cartilage Repair (Cartistem)
13.10 Leukocyte Cell Therapy (CureXcell)
13.11 Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell)
13.12 Allogeneic Cultured Keratinocytes and Fibroblasts (Gintuit)
13.13 Autologous Cultured Chondrocyte Implant (Carticel)
13.14 Autologous Cultured Chondrocytes (CHONDRON)
13.15 Autologous Chondrocytes (BioCart & BioCartII)
13.16 Amniotic Cell Therapy (NuCel)
13.17 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
13.18 Autologous Cultured Chondrocytes (Chondrotransplant DISC)
13.19 Autologous Cultured Myoblasts and Fibroblasts (Urocell)
13.20 Human Skin Replacement (CellSpray & CellSpray XP)

14. COMPETITIVE LANDSCAPE

14.1 AlloCure
14.2 Arteriocyte Medical Systems
14.3 Athersys Inc.
14.4 Baxter Healthcare Corporation
14.5 Bone Therapeutics
14.6 Celgene Corporation
14.7 Cell Medica
14.8 Cellerant Therapeutics
14.9 FibrocellScinence
14.10 Forticell Bioscience
14.11 Genzyme Corporation
14.12 Green Cross Cell
14.13 Histogenics Corporation
14.14 InnovacellBiotechnologie AG
14.15 Intrexon Corporation
14.16 Intercytex
14.17 ISTO Technologies
14.18 Macrocure
14.19 Mesoblast
14.20 Molmed
14.21 Nuo Therapeutics Inc
14.22 OmniCyte
14.23 Opexa Therapeutics
14.24 Organogenesis
14.25 Pharmicell
14.26 TCA Cellular Therapy
14.27 Stem Cell Inc.
14.28 Teva Pharmaceuticals
14.29 Tigenix
14.30 Vericel Corporation

LIST OF FIGURES

Figure 1-1: Properties of the Stem Cell
Figure 1-2: Outline to the Cell Therapy Components
Figure 2-1: History of Stem Cell Research
Figure 2-2: Promise of the Stem Cell Research
Figure 3-1: Type of Stem Cells on the Basis of Ability to Differentiate
Figure 3-2: Type of Stem Cells on the Basis of Origin
Figure 4-1: Stem Cell Therapy for Cardiovascular Diseases
Figure 4-2: Cell Therapy in Parkinson’s disease
Figure 4-3: Cell Therapy for Inflammatory Disorder
Figure 4-4: Cell Therapy for Diabetes
Figure 4-5: Strategies which are adopted for targeting the Cancer Stem Cells
Figure 5-1: Mechanism of Paracrine Signaling
Figure 5-2: Demonstration of the Endocrine Signaling
Figure 5-3: Illustration of the Autocrine Signaling
Figure 5-4: Paracrine Signaling in Heart Repair
Figure 5-5: Treatment of Alzheimer’s Diseases
Figure 7-1: Allogeneic Stem Cell Therapy
Figure 7-2: Steps of Autologous Stem Cell Therapy
Figure 8-1: Global Cell Therapy Market (US$ Billion), 2012-2022
Figure 8-2: Global – Cell Therapies Clinical Pipeline by Phase (%), 2016 till 2022
Figure 8-3: Global – Cell Therapies Clinical Pipeline by Phase (Numbers), 2016 till 2022
Figure 8-4: Global – Cell Therapies Clinical Pipeline by Phase (%), 2016 till 2022
Figure 8-5: Global – Cell Therapies Clinical Pipeline by Phase (Numbers), 2016 till 2022
Figure 10-1: Favorable Market Drivers
Figure 10-2: Factors Limiting the Cell Therapy Market
Figure 11-1: Future Projections of Stem Cell Therapy
Figure 14-1: Arteriocyte Medical Systems Clinical Pipeline
Figure 14-2: Bone Therapeutics Clinical Pipeline
Figure 14-3: Celgene Clinical Pipeline
Figure 14-4: Cellerant Therapeutics Clinical Pipeline
Figure 14-5: Fibrocell Science Clinical Pipeline
Figure 14-6: Genzyme Clinical Pipeline
Figure 14-7: Intrexon Clinical Pipeline
Figure 14-8: ISTO Clinical Pipeline
Figure 14-9: Mesoblast Clinical Pipeline
Figure 14-10: Molmed Clinical Pipeline
Figure 14-11: Pharmicell Clinical Pipeline
Figure 14-12: Tigenix Clinical Pipeline
Figure 14-13: Vericel Corporation Clinical Pipeline

LIST OF TABLES

Table 7-1: Difference between Embryonic, Adult & Induced Stem Cells
Table 8-1: List of the Blockbuster Drugs
Table 9-1: Cell Therapy Market Growth


More Publications